Condition: Herpes Zoster · Sponsor: GlaxoSmithKline
The purpose of this study is to evaluate the effect of the recombinant zoster vaccine on the risk of new diagnosis of dementia among adults aged 76 years or older in Finland. Participants will be enrolled and randomized in a 3:1 ratio to receive either recombinant zoster vaccine or placebo.
This description comes directly from the study's public registry record.
US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Espoo, Finland | Recruiting |
| GSK Investigational Site | Helsinki, Finland | Recruiting |
| GSK Investigational Site | Jarvenpaa, Finland | Recruiting |
| GSK Investigational Site | Kokkola, Finland | Recruiting |
| GSK Investigational Site | Oulu, Finland | Recruiting |
| GSK Investigational Site | Seinäjoki, Finland | Recruiting |
| GSK Investigational Site | Tampere, Finland | Recruiting |
| GSK Investigational Site | Turku, Finland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07502560